Since IMVARIA's IDTF is located in Texas, Novitas Solutions, Inc., the local Medicare Administrative Contractor (MAC), is solely responsible for evaluating coverage and payment for CPT 0877T
These agents mitigate muscle atrophy by downregulating atrophy-related factors (myostatin, MuRF1, MAFbx) and upregulating myogenic transcription factors (MyoD, MyoG) via PKA/Akt/mTOR signaling
These receptors coordinate signaling pathways that impact metabolic, inflammatory, and immune responses
Clinical trials show average weight loss of 15-22% of starting body weight over 68 weeks, with individual results ranging from 5-35% depending on genetics, diet adherence, and exercise
This might mean staying at a lower dose for a longer period, restarting titration, or using supportive treatments to help you tolerate the medication until youre ready to move back to the full therapeutic level